Vedolizumab for the prevention and treatment of postoperative recurrence in Crohn’s disease: A real- world latium net study
Digestive and Liver Disease · 2026-08 · 58 (8) · 1037-1042
DOI: 10.1016/j.dld.2026.05.002 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Digestive and Liver Disease, 2026-08. Verfasst von Angelo Del Gaudio und 17 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy. Electronic address: delgaudioangelo@gmai…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Crohn Disease, Gastrointestinal Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company Limited.
Abstract (Originalsprache)
BACKGROUND: Vedolizumab has demonstrated efficacy in randomized trials on postoperative Crohn's disease; however, real-world data on both prophylaxis and treatment of recurrence are limited. METHODS: In this retrospective multicenter study, patients with Crohn's disease treated with vedolizumab after ileocolonic resection (2018-2024) were included. Patients were stratified into a prophylaxis cohort and a recurrence-treatment cohort. Severe endoscopic recurrence (Rutgeerts ≥i3) at 6-12 months was the primary endpoint in the prophylaxis cohort. Endoscopic response (≥1-point Rutgeerts reduction) at a follow-up colonoscopy within 2 years, was evaluated in the treatment cohort. Treatment failure was defined as discontinuation of vedolizumab due to any reason. Treatment persistence was analyzed using Kaplan-Meier and multivariable Cox regression models. RESULTS: A total of 108 patients were included; 50 received vedolizumab as postoperative prophylaxis. Severe endoscopic recurrence occurred in 22% of prophylaxis patients. Prior intestinal resection (OR 5.24, 95% CI 1.03-26.61; p = 0.046) and younger age at surgery (OR 0.93, 95% CI 0.87-0.99; p = 0.042) were independently associated with severe recurrence. In the recurrence cohort (n = 58), endoscopic response was 44.8%. Overall VDZ failure occurred in 31.5%. Prophylactic use was independently associated with reduced failure (HR 0.17, 95% CI 0.05-0.53; p = 0.002). CONCLUSIONS: Vedolizumab showed sustained effectiveness for postoperative prophylaxis and more modest effectiveness in established recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy. Electronic address: delgaudioangelo@gmail.com.
- Policlinico Tor Vergata- Rome- Italy, Department of Systems Medicine- University of Rome Tor Vergata- Gastroenterology Unit-, Rome, Italy.
- Campus Bio Medico University, Unit of Digestive Disease, Rome, Italy.
- Ospedale Isola Tiberina Gemelli Isola- 00186, Gastroenterology Unit-, Rome, Italy.
- San Camillo-Forlanini Hospital, IBD Unit- Gastroenterology and Digestive Endoscopy-, Rome, Italy.
- Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy.
Förderung
- Takeda Pharmaceutical Company Limited
Zitieren
APA
Gaudio, A. D., Calabrese, E., Balestrieri, P., Pugliese, D., Fiorino, G., Vincenzo, F. D., Marafini, I., Baldaro, F., Cuccia, G., Cascella, F., Colella, A., Parisio, L., Murgiano, M., Laterza, L., Gasbarrini, A., Papa, A., Lopetuso, L. R., & Scaldaferri, F. (2026). Vedolizumab for the prevention and treatment of postoperative recurrence in Crohn’s disease: A real- world latium net study. Digestive and Liver Disease, 58(8), 1037-1042. https://doi.org/10.1016/j.dld.2026.05.002
Vancouver
Gaudio AD, Calabrese E, Balestrieri P, Pugliese D, Fiorino G, Vincenzo FD, et al. Vedolizumab for the prevention and treatment of postoperative recurrence in Crohn’s disease: A real- world latium net study. Digestive and Liver Disease. 2026;58(8):1037-1042. doi:10.1016/j.dld.2026.05.002
BibTeX
@article{Gaudio2026,
author = {Gaudio, Angelo Del and Calabrese, Emma and Balestrieri, Paola and Pugliese, Daniela and Fiorino, Gionata and Vincenzo, Federica Di and Marafini, Irene and Baldaro, Francesca and Cuccia, Giuseppe and Cascella, Fabio and Colella, Alice and Parisio, Laura and Murgiano, Marco and Laterza, Lucrezia and Gasbarrini, Antonio and Papa, Alfredo and Lopetuso, Loris Riccardo and Scaldaferri, Franco},
title = {Vedolizumab for the prevention and treatment of postoperative recurrence in Crohn’s disease: A real- world latium net study},
journal = {Digestive and Liver Disease},
year = {2026},
volume = {58},
number = {8},
pages = {1037--1042},
doi = {10.1016/j.dld.2026.05.002}
}
EUVIMED